Pricing Debate
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Otezla Is Amgen’s Main Growth Driver As Net Drug Pricing Declines
Without the newly purchased drug, Amgen’s 2020 sales would be flat, but the company hopes to enhance its psoriasis market push with its combined offering of Otezla, Enbrel and biosimilars.
Latest From Pricing Debate
Rx List Price Inflation Penalty Endorsed By US HHS Secretary
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.
FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims
Suit against agency reveals internal discussions to approve Jacobus' Ruzurgi despite Catalyst's orphan exclusivity for the same drug; Sen. Bernie Sanders urged FDA to address price of Catalyst's Firdapse (amifampridine).
Biopharma Needs A Deal On Drug Pricing As Shield Against Possible Democrat Wins – BIO’s Greenwood
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.
Trump Administration Signals Deference To Congress On Drug Pricing Policy
In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.
UK To Cut Company Payments Under Statutory Pricing Scheme
Companies that are part of the statutory pricing scheme could pay up to £6m less in 2020 under government proposals to cut percentage payments on their sales to the National Health Service.
UK Urged To Fund Rare Disease Treatments Immediately
Genetic Alliance UK says companies should be clear about how they price rare disease treatments and that the government should explain how it assesses affordability.
Drug Pricing Avoids The Limelight During State Of The Union Address
President Trump did not offer any new proposals on drug pricing during an evening featuring campaign theatrics on both sides.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.